TCM
Tang Capital Management Portfolio holdings
AUM
$1.98B
1-Year Return
21.62%
This Quarter Return
+11.67%
1 Year Return
+21.62%
3 Year Return
+290.69%
5 Year Return
+284.46%
10 Year Return
+928.34%
AUM
$688M
AUM Growth
-$127M
(-16%)
Cap. Flow
-$136M
Cap. Flow
% of AUM
-19.74%
Top 10 Holdings %
Top 10 Hldgs %
47.84%
Holding
112
New
17
Increased
24
Reduced
32
Closed
23
Top Buys
| 1 |
Axsome Therapeutics
AXSM
|
$19.3M |
| 2 |
Vaxcyte
PCVX
|
$14.4M |
| 3 |
Moderna
MRNA
|
$14.4M |
| 4 |
Mirum Pharmaceuticals
MIRM
|
$13.1M |
| 5 |
BioAtla
BCAB
|
$9.55M |
Top Sells
| 1 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
$42.3M |
| 2 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$21.2M |
| 3 |
Rocket Pharmaceuticals
RCKT
|
$20.2M |
| 4 |
Bio-Rad Laboratories Class A
BIO
|
$18.1M |
| 5 |
ALBO
Albireo Pharma, Inc. Common Stock
ALBO
|
$14.9M |
Sector Composition
| 1 | Healthcare | 98.38% |
| 2 | Consumer Discretionary | 0.64% |
| 3 | Communication Services | 0% |
| 4 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Ionis Pharmaceuticals
IONS
$9.46B
| $7.55M | 1.1% |
200,000
| – | – |
|
27
Eli Lilly
LLY
$666B
| $7.32M | 1.06% |
+20,000
| New | +$7.32M |
|
|
THRD
28
DELISTED
Third Harmonic Bio
THRD
| $7.31M | 1.06% |
+1,700,000
| New | +$7.31M |
|
|
CNCE
29
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
| $6.72M | 0.98% |
1,150,000
+146,983
| +15% | +$858K |
|
|
IMGN
30
DELISTED
Immunogen Inc
IMGN
| $6.32M | 0.92% |
1,274,853
-225,147
| -15% | -$1.12M |
|
31
Evolus
EOLS
$486M
| $6.08M | 0.88% |
809,488
+772,974
| +2,117% | +$5.81M |
|
32
CytomX Therapeutics
CTMX
$346M
| $5.62M | 0.82% |
3,510,445
+10,445
| +0.3% | +$16.7K |
|
33
Adicet Bio
ACET
$59.4M
| $5.36M | 0.78% |
+600,000
| New | +$5.36M |
|
|
GNFT
34
Genfit
GNFT
$194M
| $5.26M | 0.76% |
1,197,522
| – | – |
|
35
Galapagos
GLPG
$2.1B
| $5.1M | 0.74% |
114,950
-110,000
| -49% | -$4.88M |
|
36
Cytokinetics
CYTK
$5.95B
| $5.04M | 0.73% |
+110,000
| New | +$5.04M |
|
37
Pyxis Oncology
PYXS
$99.8M
| $4.65M | 0.68% |
3,470,700
+2,059,131
| +146% | +$2.76M |
|
38
BioNTech
BNTX
$24.9B
| $4.51M | 0.65% |
30,000
| – | – |
|
39
Ascendis Pharma
ASND
$12B
| $4.41M | 0.64% |
36,090
-30,000
| -45% | -$3.66M |
|
40
Alibaba
BABA
$312B
| $4.4M | 0.64% |
50,000
| – | – |
|
|
ITOS
41
DELISTED
iTeos Therapeutics
ITOS
| $4.23M | 0.61% |
216,700
-720,800
| -77% | -$14.1M |
|
42
Orchestra BioMed
OBIO
$148M
| $3.92M | 0.57% |
392,500
| – | – |
|
|
ALLK
43
DELISTED
Allakos
ALLK
| $3.77M | 0.55% |
447,967
-875,426
| -66% | -$7.37M |
|
44
Beam Therapeutics
BEAM
$1.88B
| $3.72M | 0.54% |
95,000
+45,000
| +90% | +$1.76M |
|
45
Amylyx Pharmaceuticals
AMLX
$887M
| $3.7M | 0.54% |
+100,000
| New | +$3.7M |
|
|
LENZ
46
LENZ Therapeutics
LENZ
$1.14B
| $3.65M | 0.53% |
157,143
| – | – |
|
47
ARS Pharmaceuticals
SPRY
$1.06B
| $3.49M | 0.51% |
409,463
| – | – |
|
|
EGRX
48
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
| $3.47M | 0.5% |
118,857
| – | – |
|
49
Insmed
INSM
$30.1B
| $3.32M | 0.48% |
166,203
-333,797
| -67% | -$6.67M |
|
50
Dynavax Technologies
DVAX
$1.17B
| $3.19M | 0.46% |
300,000
+200,000
| +200% | +$2.13M |
|